Episode 123
The FDA on Monoclonal Antibody Therapeutics: What physicians need to know, Part I
AMA president Gerald Harmon, MD, welcomes experts from the U.S. Food and Drug Administration (FDA) to discuss what prescribers need to know about COVID-19 therapeutic drugs, Paxlovid and Molnupiravir. Alternative treatment options for high-risk outpatients with mild-moderate COVID-19 are also discussed. Guest: John Farley, MD, MPH, director, Office of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA
February 11, 202210m 4s
Audio is streamed directly from the publisher (pdst.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
AMA president Gerald Harmon, MD, welcomes experts from the U.S. Food and Drug Administration (FDA) to discuss what prescribers need to know about COVID-19 therapeutic drugs, Paxlovid and Molnupiravir. Alternative treatment options for high-risk outpatients with mild-moderate COVID-19 are also discussed.
Guest: John Farley, MD, MPH, director, Office of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs, FDA
Topics
therapeuticmolnupiravirpaxlovidharmonfdanew drugsdrug evaluationjohn farleyama presidentpart seriestherapeuticspart 1gerald